“In treating status epilepticus, there is an overriding urgency to stop seizures before the 30-minute mark when seizure-associated neurologic injury can occur,” guideline co-author Shlomo Shinnar, MD, PhD, of Albert Einstein College of Medicine and Montefiore Medical Center, said in a statement. “This guideline supports an aggressive approach to treating status epilepticus and seeks to bring some structure to what can often be a chaotic and dire medical situation.”
The guideline authors note that treatment of refractory status epilepticus goes beyond the scope of the current guideline, and encourage the continuation of trials to better define the role of other anticonvulsants for the treatment of status epilepticus. Notably, the ongoing NINDS-funded ESETT trial is designed to identify the preferred second therapy for benzodiazepine-resistant status epilepticus.
The guideline has been endorsed by the Epilepsy Foundation, Child Neurology Society, Association of Child Neurology Nurses, American College of Emergency Physicians, and American Association of Neuroscience Nurses.
Glauser T, Shinnar S, Gloss D, et al. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016; 16(1): 48-61. doi:10.5698/1535-7597-16.1.48.